Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of ABR2 Ocular Lubricating Eye Drop in Dry Eye Syndrome
NCT07593404Recruiting
- Sponsor
- Pleryon Therapeutics
- Start
- May 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Open-label trial of ABR2 in dry eye syndrome (DED) (2 arms), sponsored by Pleryon Therapeutics. Primary endpoint: Number of Adverse Events at 28 days. Started May 2026; status: recruiting.
02
Drugs
ABR2
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT07593404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593404.